| Bioactivity | BPDA2 is a highly selective and competitive active site SHP2 inhibitor with IC50s of 92.0 nM, 33.39 μM, 40.71 μM for SHP2, SHP1, SHP1B, respectively. DBDA2 downregulates mitogenic and cell survival signaling and RTK expression. BPDA2 suppresses SHP2 mediated signaling and breast cancer cell phenotypes[1]. |
| Invitro | BPDA2 (0.2-3.2 μM) 以浓度依赖性方式抑制 Akt 和 ERK1/2 的基础激活[1]。BPDA2 (0.25-4.0 μM; 持续 10 天) 以浓度依赖性方式抑制乳腺癌细胞的贴壁非依赖性生长和癌症干细胞特性[1]。 Western Blot Analysis[1] Cell Line: |
| Name | BPDA2 |
| Formula | C24H30O5 |
| Molar Mass | 398.49 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Dhanaji M Lade, et al. Design and synthesis of improved active-site SHP2 inhibitors with anti-breast cancer cell effects. Eur J Med Chem. 2023 Feb 5;247:115017. |